To evaluate the systemic effects of low level laser therapy (LLLT) on the early stages of bone repair after implantation of poly-L-lactic/polyglycolic acid (PLLA-PGA) screws 24 rabbits were randomly allocated to one of two groups, experiment or control. Each animal underwent implantation of one 5 × 1.5 mm PLLA-PGA screw in each tibia (right and left). The experiment group received infrared laser irradiation (830 nm, 4 J, 100 mW, 10.1 s) over the right paw immediately after implantation and every 48 h thereafter, for a maximum of seven sessions. The control group was not irradiated. Both groups were divided into three subgroups according to the observation period (5, 15, or 30 days), after which animals were euthanized. The results observed in the left paw of experimental animals were compared with the left paws of control animals. We also compared the right and left paws of experimental animals so as to compare local and potential systemic effects. Bone specimens were analyzed to assess the extent of peri-implant bone formation, quantitative analysis revealed greater bone formation in the left tibia of experimental animals as compared to controls on 5-day follow-up. Descriptive analysis revealed slightly larger and thicker trabeculae in the irradiated animals at 5 days post-procedure. There were no significant differences at any other point in time. As used in this study, LLLT had a positive systemic effect on the early stages of bone formation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10103-013-1384-4 | DOI Listing |
Biomed Pharmacother
December 2024
College of Dental Medicine, Lincoln Memorial University, LMU Tower, 1705 St. Mary Street, Knoxville, TN 37917, USA. Electronic address:
Osteoporosis, a condition marked by the loss of bone density and mass, affects individuals of all ages. However, it becomes more prevalent and severe with aging, increasing the risk of fractures and other health complications. Recent research has highlighted a link between osteoporosis and periodontitis, a chronic gum disease, as both conditions involve excessive bone loss that can lead to significant oral health problems if untreated.
View Article and Find Full Text PDFPLoS One
December 2024
Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, Chengdu, China.
Background: Mirvetuximab Soravtansine (MIRV) is a promising antibody‒drug conjugate (ADC) that targets folate receptor alpha (FRα), which is overexpressed in several types of solid tumors. In November 2022, MIRV was approved in the USA for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who received 1-3 prior systemic treatment regimens. Therefore, high-quality evidence for its efficacy and safety in different cancers is urgently needed.
View Article and Find Full Text PDFPLoS One
December 2024
Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
Food allergies are a global health problem that continues to grow annually, with a prevalence of more than 10%. Shrimp allergy is the most common and life-threatening allergy. There is no cure for food allergies, but shrimp allergen extract (SAE) offers promise as a treatment through allergen-specific immunotherapy (AIT).
View Article and Find Full Text PDFPLoS One
December 2024
The Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Background: Exposure of critically ill patients to antibiotics lead to intestinal dysbiosis, which often manifests as antibiotic-associated diarrhoea. Faecal microbiota transplantation restores gut microbiota and may lead to faster resolution of diarrhoea.
Methods: Into this prospective, multi-centre, randomized controlled trial we will enrol 36 critically ill patients with antibiotic-associated diarrhoea.
Dermatitis
December 2024
From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. This study aimed to identify predictive factors for early and late responders to tralokinumab treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!